Results 201 to 210 of about 4,534,833 (370)

Basroparib inhibits YAP‐driven cancers by stabilizing angiomotin

open access: yesMolecular Oncology, EarlyView.
Basroparib, a selective tankyrase inhibitor, suppresses Wnt signaling and attenuates YAP‐driven oncogenic programs by stabilizing angiomotin. It promotes AMOT–YAP complex formation, enforces cytoplasmic YAP sequestration, inhibits YAP/TEAD transcription, and sensitizes YAP‐active cancers, including KRAS‐mutant colorectal cancer, to MEK inhibition.
Young‐Ju Kwon   +4 more
wiley   +1 more source

A Clinical Workflow for Evaluating Dose to Organs at Risk After Biology-Guided Radiation Therapy Delivery. [PDF]

open access: yesCancers (Basel)
Banks TI   +11 more
europepmc   +1 more source

Software Reliability: Metrics

open access: yesInternational Journal of Computer Applications, 2016
Pallavi P., Durga Patel
openaire   +1 more source

Microfluidic electro‐viscoelastic manipulation of extracellular vesicles

open access: yesFEBS Open Bio, EarlyView.
The electro‐viscoelastic manipulation as a potential method for separation of particles based on size. The particles introduced as a sheath flow migrate to the channel center under the influence of simultaneously applied electric field and pressure driven flow.
Seyedamirhosein Abdorahimzadeh   +7 more
wiley   +1 more source

Lactoferrin treatment activates acetylcholinesterase, decreasing acetylcholine levels in non‐small cell lung cancer (NSCLC) cell culture supernatants, inhibiting cell survival

open access: yesFEBS Open Bio, EarlyView.
Representation of the suggested mode of action of lactoferrin (Lf) in nonsmall cell lung cancer (NSCLC) A549 cells. Lf induces activation of caspase‐3 by activating p53 and AChE leading to decreased ACh concentrations. In turn, ACh signaling leads to activation of VEGF and AKT and blocking of caspase‐3.
Stuti Goel   +9 more
wiley   +1 more source

Home - About - Disclaimer - Privacy